Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection

(2019) Carl W. Davis et al.   CELL

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

(2018) Jae-Hoon Ko et al.   ANTIVIRAL THERAPY

Transfusion-Transmitted Infections: an Update on Product Screening, Diagnostic Techniques, and the Path Ahead

(2018) Christina L. Dean et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Anti–Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease

(2018) Jerry F Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Characterization of source plasma from self-identified vaccinated or convalescent donors during the 2009 H1N1 pandemic

(2018) Alexey Khalenkov et al.   TRANSFUSION

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone

(2018) Richard S. Tedder et al.   TRANSFUSION

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6oC

(2017) Anna Erickson et al.   TRANSFUSION

Comparison of platform technologies for assaying antibody to Ebola virus

(2017) Dianna E. Wilkinson et al.   VACCINE

Ebola virus disease: the UK critical care perspective † †This Article is accompanied by Editorial Aew068

(2016) D Martin et al.   BRITISH JOURNAL OF ANAESTHESIA

Ebola Virus Persistence in Semen of Male Survivors

(2016) Timothy M. Uyeki et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

(2016) Johan van Griensven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies

(2016) Johan van Griensven et al.   NEW ENGLAND JOURNAL OF MEDICINE

After Ebola in West Africa — Unpredictable Risks, Preventable Epidemics

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

(2016) Selidji T. Agnandji et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Management of Ebola Virus Disease in the United States and Europe

(2016) Timothy M. Uyeki et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety Considerations in the Laboratory Testing of Specimens Suspected or Known to Contain Ebola Virus

(2015) Peter C. Iwen et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field

(2015) Johan van Griensven et al.   CLINICAL INFECTIOUS DISEASES

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

(2015) Colleen S. Kraft et al.   CLINICAL INFECTIOUS DISEASES

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

(2015) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

Persistence of Ebola Virus in Ocular Fluid during Convalescence

(2015) Jay B. Varkey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain

(2015) Marta Mora-Rillo et al.   Lancet Respiratory Medicine

Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME)

(2014) Vishesh Chhibber et al.   TRANSFUSION

Balancing risk and benefit

(2013) Chelsea R. Mehr et al.   Journal of Trauma and Acute Care Surgery

Emergency use of prethawed Group A plasma in trauma patients

(2012) Martin D. Zielinski et al.   Journal of Trauma and Acute Care Surgery

Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers

(2008) Peter Schlenke et al.   TRANSFUSION